AbbVie Inc. (ABBV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABBV POWR Grades
- Quality is the dimension where ABBV ranks best; there it ranks ahead of 97.75% of US stocks.
- ABBV's strongest trending metric is Quality; it's been moving up over the last 179 days.
- ABBV's current lowest rank is in the Momentum metric (where it is better than 17.51% of US stocks).
ABBV Stock Summary
- ABBVIE INC's market capitalization of $243,272,396,747 is ahead of 99.51% of US-listed equities.
- ABBVIE INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 87.9% of US listed stocks.
- ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 90.64% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to ABBVIE INC are NVO, BABA, TMO, DHR, and PFE.
- Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to www.abbvie.com.
ABBV Valuation Summary
- In comparison to the median Healthcare stock, ABBV's price/sales ratio is 95.45% higher, now standing at 4.3.
- Over the past 118 months, ABBV's price/earnings ratio has gone up 3.2.
Below are key valuation metrics over time for ABBV.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABBV | 2022-09-01 | 4.3 | 16.7 | 19.4 | 19.0 |
| ABBV | 2022-08-31 | 4.1 | 16.2 | 18.8 | 18.5 |
| ABBV | 2022-08-30 | 4.2 | 16.4 | 19.0 | 18.7 |
| ABBV | 2022-08-29 | 4.2 | 16.4 | 19.0 | 18.7 |
| ABBV | 2022-08-26 | 4.2 | 16.5 | 19.1 | 18.8 |
| ABBV | 2022-08-25 | 4.3 | 16.8 | 19.5 | 19.1 |
ABBV Growth Metrics
- The 3 year price growth rate now stands at 94.17%.
- Its 3 year revenue growth rate is now at 73.75%.
- The 4 year net cashflow from operations growth rate now stands at 89.23%.
The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 57,349 | 22,923 | 12,637 |
| 2022-03-31 | 56,725 | 22,808 | 12,479 |
| 2021-12-31 | 56,197 | 22,777 | 11,542 |
| 2021-09-30 | 55,169 | 22,556 | 7,534 |
| 2021-06-30 | 53,729 | 20,451 | 6,663 |
| 2021-03-31 | 50,195 | 18,650 | 5,159 |
ABBV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABBV has a Quality Grade of B, ranking ahead of 80.75% of graded US stocks.
- ABBV's asset turnover comes in at 0.369 -- ranking 131st of 682 Pharmaceutical Products stocks.
- PLXP, HSTO, and ADMP are the stocks whose asset turnover ratios are most correlated with ABBV.
The table below shows ABBV's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.369 | 0.677 | 0.119 |
| 2021-06-30 | 0.359 | 0.656 | 0.102 |
| 2021-03-31 | 0.335 | 0.648 | 0.078 |
| 2020-12-31 | 0.339 | 0.664 | 0.070 |
| 2020-09-30 | 0.339 | 0.687 | 0.131 |
| 2020-06-30 | 0.372 | 0.736 | 0.147 |
ABBV Stock Price Chart Interactive Chart >
ABBV Price/Volume Stats
| Current price | $139.90 | 52-week high | $175.91 |
| Prev. close | $138.71 | 52-week low | $105.56 |
| Day low | $138.65 | Volume | 675,301 |
| Day high | $139.98 | Avg. volume | 6,883,848 |
| 50-day MA | $144.53 | Dividend yield | 4.07% |
| 200-day MA | $144.57 | Market Cap | 247.36B |
AbbVie Inc. (ABBV) Company Bio
Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.
Latest ABBV News From Around the Web
Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
3 Great Dividend Stocks to Buy in SeptemberHere's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing revenue and earnings, solid growth avenues, a juicy yield, a conservative payout ratio, and of course, an impressive history of dividend hikes. |
5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons WhyThere's no better time to build a strong watchlist of great companies than during a serious market correction. In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling. Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak. |
3 Dividend Stocks to Buy in September for Passive Income GenerationLots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. Here's how they could provide ever-increasing dividend payments to your brokerage account. Shares of Abbott Laboratories (NYSE: ABT) have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. |
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia StudyThe FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down. |
SkinMedica® Launches Firm & Tone Lotion for BodyToday, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica® Firm & Tone Lotion for Body, the first product from the professional-grade skincare line formulated to prevent and address visible signs of body skin aging for a toned look.1 It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of body skin firmness and tone, and improve the look of sagging skin.1 |
ABBV Price Returns
| 1-mo | -0.25% |
| 3-mo | -1.39% |
| 6-mo | -4.46% |
| 1-year | 31.96% |
| 3-year | 142.06% |
| 5-year | 106.12% |
| YTD | 6.27% |
| 2021 | 32.43% |
| 2020 | 27.72% |
| 2019 | 1.47% |
| 2018 | -0.96% |
| 2017 | 60.08% |
ABBV Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching ABBV
Want to do more research on AbbVie Inc's stock and its price? Try the links below:AbbVie Inc (ABBV) Stock Price | Nasdaq
AbbVie Inc (ABBV) Stock Quote, History and News - Yahoo Finance
AbbVie Inc (ABBV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...